{"pageContent": "Background: Distinguishing indolent from aggressive prostate cancer remains a key challenge for decision making regarding prostate cancer management. A growing number of biomarkers are now available to help address this need, but these have rarely been examined together in the same patients to determine their potentially additive value.", "metaData": {"source": "Prediction models for prostate cancer outcomes: what is the state of the art in 2017?\nhttps://pubmed.ncbi.nlm.nih.gov/28650863/"}}